The BiTE trial at UAB is testing 92Bio’s investigational NTB-928, a first-of-its-kind FRα-targeting T-cell engager designed to harness the patient’s own immune system against platinum-resistant ovarian cancer. The trial reflects a collaborative, patient-centered effort to explore a new treatment approach for women who have too few options after relapse.